Abstract 6938: Body Mass Index, LDL-Cholesterol Response, and Cardiovascular Outcomes with Alirocumab After Acute Coronary Syndrome
Introduction: Obesity and overweight characterize many patients with acute coronary syndrome (ACS). In the ODYSSEY OUTCOMES trial, alirocumab reduced major adverse cardiovascular events (MACE) post-ACS compared with placebo, with protocol-driven dose up-titration from 75 to 150 mg to achieve target LDL-cholesterol (...